Lv1
60 积分 2021-04-26 加入
[Guideline for HER2 testing in breast cancer (2024 version)]
2个月前
已完结
Multiple myeloma
3个月前
已关闭
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial
8个月前
已关闭
Sant M, Allemani C, Tereanu C, et al; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734
8个月前
已完结
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia
8个月前
已关闭
皖公网安备34019202002308
